Tuesday, 13 October 2026European Markets

KBC And SPAREBANK 1 SØRØ Have A High Dividend Yield And Return On Equity In The Banks—Regional Industry.

Loading stream...

(VIANEWS) - KBC (KBC.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Banks—Regional industry.

Financial Asset Price Forward Dividend Yield Return on Equity
KBC (KBC.BR) €66.68 9.1% 13.72%
SPAREBANK 1 SØRØ (SOON.OL) kr50.80 5.21% 10.73%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. KBC (KBC.BR)

9.1% Forward Dividend Yield and 13.72% Return On Equity

KBC Group NV, together with its subsidiaries, provides integrated bank-insurance services primarily for retail, private banking, small and medium sized enterprises, and mid-cap clients. The company offers demand deposits and savings accounts; home and mortgage loans; consumer finance and SME funding services; credit, investment fund and asset management, and life and non-life insurance; and cash management, payments, trade finance, lease, money market, capital market products, and stockbroking services. It also provides digital and mobile banking services. The company was formerly known as KBC Bank and Insurance Holding Company NV and changed its name to KBC Group NV in March 2005. KBC Group NV was incorporated in 1935 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, KBC has a trailing twelve months EPS of €7.43.

PE Ratio

KBC has a trailing twelve months price to earnings ratio of 8.97. Meaning, the purchaser of the share is investing €8.97 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.72%.

Yearly Top and Bottom Value

KBC's stock is valued at €66.68 at 12:40 EST, under its 52-week high of €72.46 and way higher than its 52-week low of €45.53.

Moving Average

KBC's value is higher than its 50-day moving average of €63.71 and above its 200-day moving average of €61.98.

More news about KBC.

2. SPAREBANK 1 SØRØ (SOON.OL)

5.21% Forward Dividend Yield and 10.73% Return On Equity

SpareBank 1 Sørøst-Norge provides various banking products and services for private and corporate customers in Norway. The company offers mobile and online banking, card, account, and payment services. It also provides mortgage, car, boat, consumer, and other vehicle loans as well as refinancing, micro savings, investment, pension, and property related services. In addition, the company offers daily operations, get paid, loans and financing, and pension related products. Further, it provides business and personnel insurance as well as savings and investment products. The company was founded in 1859 and is headquartered in Sandefjord, Norway.

Earnings Per Share

As for profitability, SPAREBANK 1 SØRØ has a trailing twelve months EPS of kr4.79.

PE Ratio

SPAREBANK 1 SØRØ has a trailing twelve months price to earnings ratio of 10.61. Meaning, the purchaser of the share is investing kr10.61 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.73%.

Volume

Today's last reported volume for SPAREBANK 1 SØRØ is 18427 which is 13.33% below its average volume of 21262.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is 40% and 37.3%, respectively.

More news about SPAREBANK 1 SØRØ.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com